Charles River Laboratories International, Inc. (CRL)
| Market Cap | 17.06B +85.3% |
| Revenue (ttm) | 4.00B -0.7% |
| Net Income | -238.46M |
| EPS | -4.88 |
| Shares Out | 47.74M |
| PE Ratio | n/a |
| Forward PE | 28.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,175,928 |
| Open | 347.59 |
| Previous Close | 345.37 |
| Day's Range | 345.89 - 357.77 |
| 52-Week Range | 146.20 - 357.77 |
| Beta | 1.40 |
| Analysts | Buy |
| Price Target | 314.20 (-12.06%) |
| Earnings Date | Nov 4, 2026 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, ins... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $314.2, which is a decrease of -12.06% from the latest price.
News
Charles River, Labcorp, FDA to partner on study of drug abuse potential
Charles River (CRL) Laboratories announced a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) and Labcorp for developing sensitive screening tools to quantify and rank...
Labcorp, Charles River and FDA to collaborate to evaluate drug abuse potential
Labcorp (LH) announced a collaboration with the FDA and Charles River Laboratories (CRL) to advance the science used to evaluate a medicine’s abuse potential, or the likelihood that it could…
Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new...
Charles River announces collaboration with Magellan Stem Cells
Charles River (CRL) Laboratories and Magellan Stem Cells announce their collaboration to support Magellan in the development and clinical advancement of its proprietary stem cell-based therapies and r...
Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Magellan Stem Cells, a private Australian biotech and cell-therapy firm, announce thei...
Charles River price target raised to $340 from $300 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Charles River (CRL) to $340 from $300 and keeps an Overweight rating on the shares.
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.
Charles River, Autolomous announce launch of Apollo Orchestrate
Charles River (CRL) Laboratories International and Autolomous announced the launch of Apollo Orchestrate, a new capability within Charles River’s Apollo platform that connects and digitizes laboratory...
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new c...
Charles River resumed with a Buy at UBS
UBS resumed coverage of Charles River (CRL) with a Buy rating and $357 price target UBS assumed coverage of the contract research organization industry with a constructive view on fundamentals,…
NorthStrive partners with Charles River to advance EL-22, EL-32 programs
PMGC (ELAB) Holdings (PMGC) announced that its subsidiary, NorthStrive Biosciences has executed a Statement of Work with Charles River Laboratories (CRL) to conduct analytical characterization support...
Charles River price target raised to $330 from $300 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Charles River (CRL) to $330 from $300 and keeps a Buy rating on the shares after having attended the company’s…
Charles River price target raised to $340 from $305 at Jefferies
Jefferies analyst David Windley raised the firm’s price target on Charles River (CRL) to $340 from $305 and keeps a Buy rating on the shares. Charles River’s long-range plan for…
Charles River price target raised to $322 from $282 at RBC Capital
RBC Capital raised the firm’s price target on Charles River (CRL) to $322 from $282 and keeps an Outperform rating on the shares after the company’s investor day exceeded consensus…
Charles River price target raised to $320 from $300 at Deutsche Bank
Deutsche Bank analyst Justin Bowers raised the firm’s price target on Charles River (CRL) to $320 from $300 and keeps a Buy rating on the shares following the analyst day.
Charles River price target raised to $330 from $320 at Evercore ISI
Evercore ISI raised the firm’s price target on Charles River (CRL) to $330 from $320 and keeps an Outperform rating on the shares.
Charles River price target raised to $295 from $264 at Mizuho
Mizuho raised the firm’s price target on Charles River (CRL) to $295 from $264 and keeps a Neutral rating on the shares following the investor day. The company introduced intermediate-term…
Charles River price target raised to $334 from $291 at Baird
Baird raised the firm’s price target on Charles River (CRL) to $334 from $291 and keeps an Outperform rating on the shares.
Charles River price target raised to $330 from $300 at Barclays
Barclays raised the firm’s price target on Charles River (CRL) to $330 from $300 and keeps an Overweight rating on the shares after meeting with management. The firm says “appropriately…
Charles River Laboratories International Transcript: Investor Day 2026
Pathway to Purpose drives modernization, scientific leadership, and client-centric growth, with $300M in cost savings targeted by 2030. Financial goals include 5%-7% organic sales CAGR, ~24% margins, and double-digit EPS growth, supported by investments in BioA, NAMs, and digital platforms.
Charles River Laboratories International Slides: FY 2026
Charles River Laboratories International has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 24, 2026.
Charles River Laboratories International Press release: FY 2026
Charles River Laboratories International issued a press release on September 24, 2026, disclosing material business information to investors.
Charles River Associates reaffirms FY26 EPS view at upper end of $11.15-$11.45
Consensus $11.33. Reaffirms revenue growth at upper end of 0%-1%; non-GAAP operating margin 21%-21.3%. Charles River (CRL) Laboratories International will host its 2026 Investor Day. Birgit Girshick, ...
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day.
Charles River price target raised to $330 from $250 at Argus
Argus raised the firm’s price target on Charles River (CRL) to $330 from $250 and keeps a Buy rating on the shares. The firm is citing the company’s stronger EPS…